UK-based Pharma giant GSK plc reported its Q2 earnings earlier today. GSK plc exceeded Q2 2024 expectations with revenue up 13%, operating profit up 18%, and EPS up 17%. GSK upgraded full-year ...

As we can see above, GSK has delivered a solid quarter of performance, outperforming analysts expectations across most measures, and driven by strong performances from the likes of shingles ...

The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work ...

GSK and S&P 500 Performance During 2007-08 Crisis. GSK stock declined from $53 in September 2007 (pre-crisis peak) to around $28 in March 2009, as the markets bottomed out, implying it lost 48% of ...

The most recent trading session ended with GSK (GSK) standing at $42.79, reflecting a -0.09% shift from the previouse trading day's closing. This move was narrower than the S&P 500's daily loss of ...

Why GSK Stock Rocketed Nearly 6% ... a performance that easily eclipsed the 0.7% rise of the ... our expert team of analysts issues a “Double Down” stock recommendation for companies that they ...

Additionally, GSK has a PEG Ratio of 1.2 and a Price/Cash Flow ratio of 7.3X. Value investors should also note GSK's Price/Sales ratio of 2X. A company's earnings performance is important for ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.